CARD11功能获得性突变上调BCL2A1表达并促进B细胞淋巴瘤对联合靶向治疗耐药
本研究对接受抗CD20、BCL2和布鲁顿酪氨酸激酶联合靶向治疗(OAsIs试验)的套细胞淋巴瘤患者进行纵向基因组和单细胞RNA测序分析,发现CARD11突变导致NF-κB1靶基因BCR非依赖性过表达,直接增加抗凋亡基因BCL2A1转录,从而对维奈克拉和OAsIs联合方案耐药;MALT1蛋白酶抑制可降低BCL2A1等耐药基因表达,与BCL2抑制协同诱导细胞死亡。
要点
- CARD11功能获得性突变通过上调BCL2A1转录介导对维奈克拉及OAsIs联合方案的耐药。
- 基于耐药亚克隆转录谱设计的16基因耐药特征也可预测常规化疗MCL患者的预后。
- MALT1蛋白酶抑制可降低BCL2A1等耐药基因表达,与BCL2抑制协同诱导细胞死亡。
核心结论
- 研究揭示了B细胞淋巴瘤对联合靶向治疗耐药的机制,并提供了克服侵袭性B细胞淋巴瘤耐药的新策略。
研究设计与样本
- 对接受针对CD20、BCL2和布鲁顿酪氨酸激酶联合靶向治疗(OAsIs试验,NCT02558816)的套细胞淋巴瘤患者进行纵向基因组和单细胞RNA测序分析。
主要发现
- 体内出现对OAsIs联合方案具有选择性优势的亚克隆,耐药细胞的特征是BCR非依赖性的NF-κB1靶基因过表达,尤其归因于CARD11突变。
- CARD11功能获得性突变不仅导致BCR非依赖性,还直接增加抗凋亡基因BCL2A1的转录,导致对维奈克拉和OAsIs联合方案耐药。
- 基于OAsIs耐药亚克隆的转录谱设计的16基因耐药特征也可预测接受常规化疗的套细胞淋巴瘤患者,提示存在共同的逃逸机制。
- MALT1蛋白酶抑制降低包括BCL2A1在内的OAsIs耐药相关基因表达,与BCL2抑制联合在体外和体内协同诱导细胞死亡,与CARD11突变状态无关。
临床怎么用
- 作者认为MALT1蛋白酶抑制联合BCL2抑制是克服CARD11依赖性NF-κB1信号介导的耐药的新策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A strategy combining targeted therapies is effective in B-cell lymphomas (BCL), such as mantle cell lymphoma (MCL), but acquired resistances remain a recurrent issue. In this study, we performed integrative longitudinal genomic and single-cell RNA-sequencing analyses of patients with MCL who were treated with targeted therapies against CD20, BCL2, and Bruton tyrosine kinase (OAsIs trial). We revealed the emergence of subclones with a selective advantage against OAsIs combination in vivo and showed that resistant cells were characterized by B-cell receptor (BCR)-independent overexpression of NF-κB1 target genes, especially owing to CARD11 mutations. Functional studies demonstrated that CARD11 gain of function not only resulted in BCR independence but also directly increased the transcription of the antiapoptotic BCL2A1, leading to resistance against venetoclax and OAsIs combination. Based on the transcriptional profile of OAsIs-resistant subclones, we designed a 16-gene resistance signature that was also predictive for patients with MCL who were treated with conventional chemotherapy, underlying a common escape mechanism. Among druggable strategies to inhibit CARD11-dependent NF-κB1 transduction, we evaluated the selective inhibition of its essential partner MALT1. We demonstrated that MALT1 protease inhibition led to a reduction in the expression of genes involved in OAsIs resistance, including BCL2A1. Consequently, MALT1 inhibition induced synergistic cell death in combination with BCL2 inhibition, irrespective of CARD11 mutational status, both in vitro and in vivo. Taken together, our study identified mechanisms of resistance to targeted therapies and provided a novel strategy to overcome resistance in aggressive BCL. The OAsIs trial was registered at www.clinicaltrials.gov #NCT02558816.
引用
- Decombis S, Bellanger C, Le Bris Y, et al. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 2023. PMID: 37562004. doi:10.1182/blood.2023020211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。